Arcutis Biotherapeutics, Inc.
ARQT
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.0B
$23.90
▲ +1.01%
P/E
114.63
Mkt Cap
$3.0B
52-Wk Range
$16.57–$31.77
52-Week Range
$16.57 - $31.77
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 37.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary topical formulation technology enabling deeper skin penetration
- First-mover advantage in roflumilast topical space with Phase III data
- Diversified pipeline addressing multiple high-prevalence dermatological indications
- Non-systemic approach reducing safety concerns versus oral alternatives
Bear Case
2 risks
- Above-average volatility (beta 1.5).
- Growth premium of 2.3x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Moderate growth ahead
ARQ-151 regulatory approval and commercialization for psoriasis and atopic dermatitis
Value
Growth premium of 2.3x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Strong
+11.0% over 3m
Quality
Excellent
High-growth business (76% revenue growth, 91% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying ARQT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
AUG 5, 2026
Reported EPS of $0.11 vs $0.06 consensus (+99.7% surprise). Revenue of $129.9M vs $118.9M expected (+9.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+99.7%
Revenue trend · last 8Q
—
+428%
+33%
+164%
+122%
+81%
+60%
+59%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$44.8M
$71.4M
$65.8M
$81.5M
$99.2M
$129.5M
$105.4M
$129.9M
Margins · last 8Q
Gross
91.6%
Operating
12.7%
Profit
11.6%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Aug 6, 2026
vs Industry
How ARQT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related